ArticleJournal of cellular and molecular medicine2022
Pyroptosis-related molecular classification and immune microenvironment infiltration in breast cancer: A novel therapeutic target.
Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies.Cell death discovery · 2026Review
- Curcumin as a Dual Modulator of Pyroptosis: Mechanistic Insights and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Identification of pyroptosis-associated miRNAs in the immunoscape and prognosis of hepatocellular carcinoma.BMC cancer · 2024Article
- Research progress on the effect of pyroptosis on the occurrence, development, invasion and metastasis of colorectal cancer.World journal of gastrointestinal oncology · 2024Review
- Quercetin inhibits caspase-1-dependent macrophage pyroptosis in experimental folic acid nephropathy.Chinese medicine · 2024Article
- Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Identification of a novel pyroptosis-related gene signature in human spermatogenic dysfunction.Journal of assisted reproduction and genetics · 2023Article
- Effect of tumor-associated macrophages on the pyroptosis of breast cancer tumor cells.Cell communication and signaling : CCS · 2023Review
- Pyroptosis-related molecular classification and immune microenvironment infiltration in breast cancer: A novel therapeutic target.Journal of cellular and molecular medicine · 2022Article
- A pyroptosis-related gene signature for prognostic and immunological evaluation in breast cancer.Frontiers in oncology · 2022Article
- Targeted Pyroptosis Is a Potential Therapeutic Strategy for Cancer.Journal of oncology · 2022Review
- A Prognostic Signature Consisting of Pyroptosis-Related Genes and SCAF11 for Predicting Immune Response in Breast Cancer.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The underlying role of pyroptosis in breast cancer (BC) remains unknown. Herein, we investigated the correlations of 33 pyroptosis-related genes (PRGs) with immune checkpoints and immune cell infiltrations in BC patients based on The Cancer Genome Atlas cohort (n = 996) and Gene Expression Omnibus cohort (n = 3,262). Enrichment analysis revealed that these PRGs mainly functioned in pyroptosis, inflammasomes and regulation of autophagy pathway. Four prognostic independent PRGs (CASP9, TIRAP, GSDMC and IL18) were identified. Then, cluster 1/2 was recognized using consensus clustering for these four PRGs. Patients from cluster 1 had a favourable prognosis and diverse immune cell infiltrations. A nomogram was developed based on age, TNM stage, tumour subtype and pyroptosis score. Patients with the high-risk group exhibited worse 5-year OS, and the result was consistent in the external cohort. Additionally, high-risk group patients were associated with downregulated immune checkpoint expression. Further analysis suggested that the high-risk group patients were associated with a higher IC50 of paclitaxel, doxorubicin, cisplatin, methotrexate and vinorelbine. In summarizing, the pyroptosis score-based nomogram might serve as an independent prognostic predictor and could guide medication for chemotherapy. Additionally, it may bring novel insight into the regulation of tumour immune microenvironment in BC and help to achieve precision immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.